COMPARATIVE ANALYSIS OF THE EFFICIENCY OF TOREMIFENE, TAMOXIFEN, AND LETROZOLE IN TREATMENT OF PATIENTS WITH DISSEMINATED BREAST CANCER

Zejnalov R.S., Musaev I.N., Giyasbejli S.R., Dadasheva N.R., Gasanzade D.A., Yusifov A.I., Akhadova N.A.

The findings are reported to a randomized clinical study aiming to comparetheefficiency andtoxicity levels of tamoxifen (Tamoxifen), toremifene (Fareston®), and letrozole (Femara®) in treatment of disseminated breast cancer in women with theestablished receptor status. The study involved 451 patients who were randomized into four groups: 117 (25.9%) were treated with tamoxifen 20 mg(Tam 20); 115 (25.5%) with toremifene 60 mg(Tor 60); 106 (23.5%) with toremifene 240 mg (Tor 240), and 113 (25.1%) with letrozole 2.5 mg (Let 2.5). The main criteria of the efficiency included objective effect and median of the remittance duration. The subjective effect and toxicity signs were used as addition criteria. The frequency of the objective response to treatment (full + partial regression) was 25.6 for Tam 20; 33.0 for Tor 60; 41.5 for Tor 240; and 35.4% for Let 2.5 respectively. The median of the remittance duration in the groups was 9.2 months(Tam 20), 11.3 months(Tor 60), 14.5 months (Tor 240), and 13.1 months (Let 2.5). The treatment was well tolerated in all the groups. Results of studies were presented on 9th Congress of Japanese mammologist at January 21, 2006 in Fukuoka, Japan.